You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
海南海藥(000566.SZ):加快公司債權回收 與賽諾生物簽署債務抵償框架協議
格隆匯 12-21 21:48

格隆匯12月21日丨海南海藥(000566.SZ)公佈,此前披露,2018年公司與重慶賽諾生物藥業股份有限公司(“賽諾生物”)簽署複方紅豆杉膠囊全國代理權協議,同時公司向賽諾生物提供財務資助不超過人民幣3億元,資金佔用費年費率為8%,該額度在首筆借款到賬之日起三年內有效,並以賽諾生物複方紅豆杉膠囊的藥品批准文號(國藥準字Z20026350號)作為對海南海藥3億元借款的擔保保障措施。公司於2018年12月3日召開的第九屆董事會第二十六次會議審議通過了《關於擬取得重慶賽諾生物藥業股份有限公司獨家品種複方紅豆杉膠囊全國代理權暨向其提供財務資助的議案》

上述財務資助於2021年12月18日到期,公司向賽諾生物提供財務資助本金3億元,應收利息和罰息84,619,206.56元,合計為384,619,206.56元,佔公司最近一期經審計淨資產的9.68%。

2021年12月18日,公司第十屆董事會第二十一次會議以9票同意,0票反對,0票棄權審議通過了《關於簽署債務抵償框架協議的議案》。

為有效解決上述財務資助問題,加快公司債權回收,防範經營風險,落實雙方的債務償付問題,經雙方充分溝通,公司與賽諾生物簽署了《債務抵償框架協議》,賽諾生物以其複方紅豆杉膠囊藥品批件及相關資產根據評估價值抵償其債務,不足抵償部分,將由賽諾生物以現金或其他資產抵償。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account